Global Companion Diagnostics Market 2014-2018


◆タイトル:Global Companion Diagnostics Market 2014-2018
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:pdf / 英語
Single UserUSD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five UserUSD2,800 ⇒換算¥308,000見積依頼/購入/質問フォーム
Enterprise License(社内共有可)USD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。



About Companion Diagnostics
Companion diagnostics is used to identify suitable patients to whom specific drugs can be administered and it monitors the prognosis of the effects of the drug(s) on the disease. This concept of combining a drug with a diagnostic test is termed predictive medicine or personalized medicine. The companion diagnostic test has the ability to predict disease risk, diagnose disease, and monitor the therapeutic response. The tests enable physicians to make informed decisions on the type of drugs to use and the dosage in order to attempt to reduce the mortality rate of diseases such as cancer and neurodegenerative disorders.
TechNavio’s analysts forecast the Global Companion Diagnostics market will grow at a CAGR of 18.59 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Companion Diagnostics market for the period 2013-2018. To calculate the market size, the report considers revenue generated from the sales of companion diagnostic tests and associated kits provided by the vendors. It also presents the vendor landscape and a corresponding detailed analysis of key five vendors in the Global Companion Diagnostics market. The market is highly fragmented, with the presence of many small and large vendors. It includes vendors that operate across the globe and have a substantial presence in North America and the European Union. In addition, the report discusses the major drivers that influence the growth of the Global Companion Diagnostics market. It also outlines the challenges faced by vendors and the market at large, as well as the key trends that are emerging in the market.
TechNavio’s report, the Global Companion Diagnostics Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Companion Diagnostics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
Key Vendors
• Abbott Laboratories
• Agilent Technologies Inc.
• bioMérieux SA
• Qiagen N.V.
• Roche Holding AG
Other Prominent Vendors

• 20/20 Genesystems Inc.
• A & G Pharmaceutical Inc.
• AccuTheranostics Inc.
• Alacris Theranostics GmbH
• AutoGenomics Inc.
• Biogenex Laboratories Inc.
• Leica Biosystems GmbH
• Life Technologies Inc.
• Luminex Corp.
• Spartan Bioscience Inc.
• TheraDiag S.A.
• Theranostics Health Inc.
• Ventana Medical Systems Inc.
Key Market Driver
• Increasing Focus on Reducing the Cost of Drug Discovery and Development.
• For a full, detailed list, view our report.
Key Market Challenge
• High Cost Associated with the Development of Companion Diagnostics.
• For a full, detailed list, view our report.
Key Market Trend
• Increase in Growth Strategies among Vendors
• For a full, detailed list, view our report.
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.


1 Executive Summary
2 List of Abbreviations
3 Scope of the Report
3.1 Market Overview
3.2 Product Offerings
4 Market Research Methodology
4.1 Market Research Process
4.2 Research Methodology
5 Introduction
6 Market Landscape
6.1 Market Overview
6.2 Market Size and Forecast
6.3 Five Forces Analysis
7 Geographical Segmentation
8 Buying Criteria
9 Market Growth Drivers
10 Drivers and their Impact
11 Market Challenges
12 Impact of Drivers and Challenges
13 Market Trends
14 Trends and their Impact
15 Vendor Landscape
15.1 Competitive Scenario
15.1.1 Key News
15.1.2 Mergers and Acquisitions
15.2 Other Prominent Vendors
16 Key Vendor Analysis
16.1 Agilent Technologies Inc.
16.1.1 Business Overview
16.1.2 Business Segmentation
16.1.3 Key Information
16.1.4 SWOT Analysis
16.2 Abbott Laboratories
16.2.1 Business Overview
16.2.2 Business Segmentation
16.2.3 Key Information
16.2.4 SWOT Analysis
16.3 bioMérieux SA.
16.3.1 Business Overview
16.3.2 Business Segmentation
16.3.3 Key Information
16.3.4 SWOT Analysis
16.4 Genomic Health Inc.
16.4.1 Business Overview
16.4.2 Business Segmentation
16.4.3 Key Information
16.4.4 SWOT Analysis
16.5 Roche Holding AG
16.5.1 Business Overview
16.5.2 Business Segmentation
16.5.3 Key Information
16.5.4 SWOT Analysis
16.6 Qiagen N.V.
16.6.1 Business Overview
16.6.2 Business Segmentation
16.6.3 Key Information
16.6.4 SWOT Analysis
17 Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global in vitro Diagnostic Market 2013-2018 (US$ billion)
Exhibit 3: Global In vitro Diagnostic Market 2013
Exhibit 4: Global Companion Diagnostics Market 2013-2018 (US$ billion)
Exhibit 5: Comparative Analysis of Y-o-Y Growth Rates of Companion Diagnostic and IVD, Global Markets (2013-2018)
Exhibit 6: Global Companion Diagnostics Market Segmentation by Indication, 2013
Exhibit 7: Global Companion Diagnostics Market Segmentation by Indication, 2013
Exhibit 8: Global Companion Diagnostics Market, By Geography 2013
Exhibit 9: Business Segmentation of Agilent Technologies Inc.
Exhibit 10: Business Segmentation of Abbott Laboratories
Exhibit 11: Business Segmentation of bioMérieux SA.
Exhibit 12: Business Segmentation of Roche Holding AG.
Exhibit 13: Business Segmentation of Qiagen N.V.


Abbott Laboratories, Agilent Technologies Inc., bioMérieux SA, Qiagen N.V., Roche Holding AG, 20/20 Genesystems Inc. , A & G Pharmaceutical Inc., AccuTheranostics Inc., Alacris Theranostics GmbH, AutoGenomics Inc., Biogenex Laboratories Inc., LeicaBiosystems GmbH, Life Technologies Inc., Luminex Corp., pHLOGISTIX LLC, Spartan Bioscience Inc., TheraDiag S.A., Theranostics Health Inc., Ventana Medical Systems Inc.